Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Abstract Introduction The Asian Pacific Association for the Study of the Liver (APASL)
convened an international working party on the management of hepatocellular carcinoma …

This report explores the available curative molecules directed against hepatocellular
carcinoma (HCC). Limited efficiency as well as other drawbacks of existing molecules led to …

Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a
multifaceted molecular pathogenesis. Current evidence indicates that during …

Hepatocellular carcinoma (HCC) is a major health problem. Most patients with HCC
experience a recurrence after resection/ablation or are diagnosed at advanced stages …

Cirrhosis results from progressive fibrosis and is the final outcome of all chronic liver
disease. It is among the ten leading causes of death in United States. Cirrhosis can result in …

Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer‐related
mortality in the United States. Because of the lack of viable treatment options for HCC …

Objective: To review the literature on current management of hepatocellular carcinoma
(HCC). Background: Hepatocellular carcinoma represents one of the most common …